MSNeuraxpharm pays US$650m for MS drug com...TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy. more ➔
DealMithra Pharmaceuticals SA in €17m licenc...Mithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada. more ➔
ScienceBacterial-fungal consortium denitrifies...A German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%. more ➔
CollaborationRetinopathy: Golgi and Breye join forcesMilan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders. more ➔
FinancingNK cell therapy company NK:IO raises see...British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m. more ➔
DealAlnylam in US$2.8bn biobucks deal with R...siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive. T more ➔
IPResistance blocker of immune checkpoint...The EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system. more ➔
Alzheimer'sLilly presents impressing results for Al...Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients. more ➔
ScienceBiomethane fuel offers negative carbon f...Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study. more ➔
RecyclingCarbios raises €141m to boost enzymatic...In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015. more ➔
